News
Oncodesign Precision Medicine Receives Support from The Michael J. Fox Foundation to Advance Develop
1+ hour, 15+ min ago (291+ words) This next step in OPM-201s development follows the reacquisition of all rights to the program from its collaboration partner Servier in December 2024. OPM partners with expert collaborators on opportunities and assets delivered by its innovative technologies outside of oncology. These…...
Demeetra Publication in Biotechnology Progress Validates Integrated Platforms for Commercial Cell Li
6+ hour, 38+ min ago (563+ words) Peer-reviewed study demonstrates precision genome editing, stable integration, and high-producing CHO platforms for commercial biomanufacturingLEXINGTON, Ky.--(BUSINESS WIRE)--Demeetra AgBio (Demeetra) today announced the publication of a peer-reviewed research article in Biotechnology Progress validating the performance of its integrated cell…...
Simulations Plus Convenes Industry and Regulatory Leaders to Define Responsible AI in MIDD
8+ hour, 35+ min ago (121+ words) Expert panel at the 2026 ASCPT Annual Meeting brings together leaders with industry and regulatory experience to explore practical, accountable AI implementation During the session, panelists will discuss how AI is currently being deployed as part of model-informed drug development (MIDD) workflows....
Thermo Fisher Scientific Launches New Color-Based (Chromogenic) Culture Media to Help Detect Candida
1+ day, 8+ hour ago (462+ words) Brilliance Candida 2 Agar and Spectra Candida Agar support earlier detection, faster outbreak response and more informed treatment decisions in healthcare settings*WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today announced the launch of Thermo…...
Orca Bio to Present Clinical Data on Its Pipeline of High-Precision Cell Therapies at the 52nd Annua
1+ day, 19+ hour ago (483+ words) Patient reported outcomes with Orca-T" from the pivotal Precision-T Phase 3 study will be presented including quality of life and rates of rehospitalizations compared to conventional alloHSCT Data evaluating the use of Orca-T with reduced intensity conditioning versus PTCy for the…...
The End of "What's for Dinner?" - MDCE Launches AI App That Thinks Like a Chef! Download Snapshot Re
4+ day, 17+ hour ago (213+ words) MESA, ARIZONA / ACCESS Newswire / February 27, 2026 / Medical Care Technologies, Inc. (OTC PINK:MDCE) today announced the official launch of its first consumer-based artificial intelligence mobile application, Snapshot Recipes, now available on both the Apple iOS App Store and the Google Play…...
IGC Pharma Files Utility Patent Applications Covering AI-Based Data Harmonization Architecture Suppo
5+ day, 10+ hour ago (724+ words) POTOMAC, MD / ACCESS Newswire / February 26, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, today announced the filing of utility patent applications covering the architectural framework of its Agentic Harmonization…...
Niagen Bioscience Secures New U.S. Patent Covering Intravenous and Injection Formulations and Method
6+ day, 8+ hour ago (231+ words) Niagen Bioscience continuously evaluates and investigates next-generation NAD+ precursors at the forefront of the burgeoning healthy aging category. The company owns and licenses a robust, secure portfolio of over 100 patents covering its flagship Niagen ingredient, the most efficient and high-quality…...
Leveragen Strengthens Global Intellectual Property Estate with Issuance of Singularity Platform Pate
6+ day, 8+ hour ago (504+ words) Leveragen Strengthens Global Intellectual Property Estate with Issuance of Singularity Platform Pate'PharmiWeb.com Leveragen Strengthens Global Intellectual Property Estate with Issuance of Singularity Platform Patent in Japan BOSTON--(BUSINESS WIRE)--#ADCs--Leveragen, Inc., a Boston-based biotechnology company advancing next-generation in…...
Kivu Bioscience Presents KIVU-305 Preclinical Data at World ADC London 2026 and Advances into Phase
6+ day, 8+ hour ago (426+ words) Kivu Bioscience Presents KIVU-305 Preclinical Data at World ADC London 2026 and Advances into Phase'PharmiWeb.com Kivu Bioscience Presents KIVU-305 Preclinical Data at World ADC London 2026 and Advances into Phase 1 Clinical Trial - Receives Australian HREC Approval and CTN Clearance for First-in-Human…...